Mizuho Securities analyst Uy Ear maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 46.0% and a total average return of 5.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta experienced a significant third-quarter performance surpassing expectations in terms of overall and Elevidys revenue. The company's consistent guidance for Elevidys seems to err on the side of caution.
Sales of Elevidys and the exon-skipping franchise surpassed consensus expectations, and the management's outlook for Q4 Elevidys remains intact, which may set the stage for further success barring significant holiday disruptions. There's anticipation for a possible increase to the FY25 guidance come January, though current market valuations reflect a perspective that views the franchise through a five-year lens leading up to the loss of exclusivity.
Sarepta's product, Elevidys, exhibited sales growth in the third quarter that surpassed expectations, accompanied by optimistic remarks from management regarding the product's market introduction. All indications suggest that Elevidys has the potential to evolve into a product generating several billions in sales, which could be further enhanced by a series of gene therapy debuts anticipated over the forthcoming five years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
